Advertisement

Pancreatic Cancer pp 1073-1088 | Cite as

Adjuvant Chemoradiation Therapy for Pancreatic Cancer

  • Adeel Kaiser
  • William F. Regine
  • Naimish Pandya
  • Michael C. Garofalo
Reference work entry

Abstract

Despite newer treatment modalities, overall outcome for pancreatic cancer remains poor and has changed very little during the past 30 years. Surgery remains the mainstay, but delivery of adjuvant postoperative therapy has been shown to be essential for long-term survival. Large, prospective randomized studies have revealed conflicting data on whether chemotherapy alone or combination chemoradiation is optimal. They have also triggered debates regarding the sequencing of adjuvant therapy strategies. Unfortunately, marked discrepancies exist with patient selection as well as trial design among these studies, resulting in inadequate comparisons of their conclusions. Nevertheless, like other gastrointestinal malignancies, it appears that adjuvant combination chemoradiation is superior to chemotherapy alone when the data is critically analyzed. This critical examination of the published data to date is provided in the forthcoming chapter, along with an assessment of what is needed for future trials to determine the optimal adjuvant treatment modality and improve overall outcome for pancreatic cancer patients.

Keywords

Radiotherapy Radiation Adjuvant radiation Adjuvant radiotherapy Adjuvant chemoradiation Pancreatic cancer Cancer of the pancreas Algenpantucel-l SMAD4 

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Warshaw AL, Fernandez-del CC. Pancreatic carcinoma. N Engl J Med. 1992;326(7):455–65.CrossRefGoogle Scholar
  3. 3.
    Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/− 5 fluorouracil. Int J Radiat Oncol Biol Phys. 1993;26(3):483–9.CrossRefGoogle Scholar
  4. 4.
    Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60.CrossRefGoogle Scholar
  5. 5.
    Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66(1):56–61.CrossRefGoogle Scholar
  6. 6.
    Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37(3):1519–24.CrossRefGoogle Scholar
  7. 7.
    Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1991;21(5):1137–43.CrossRefGoogle Scholar
  8. 8.
    Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10(4):511–8.CrossRefGoogle Scholar
  9. 9.
    Yamada S, Fujii T, Shimoyama Y, et al. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas. 2015;44(4):660–4.CrossRefGoogle Scholar
  10. 10.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.CrossRefGoogle Scholar
  11. 11.
    Mulcahy MF. Adjuvant therapy for pancreas cancer: advances and controversies. Semin Oncol. 2007;34(4):321–6.CrossRefGoogle Scholar
  12. 12.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefGoogle Scholar
  13. 13.
    Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.CrossRefGoogle Scholar
  14. 14.
    Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865–7.CrossRefGoogle Scholar
  15. 15.
    Haslam JB, Cavanaugh PJ, Stroup SL. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer. 1973;32(6):1341–5.CrossRefGoogle Scholar
  16. 16.
    Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006–10.Google Scholar
  17. 17.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782–774.CrossRefGoogle Scholar
  18. 18.
    Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26.CrossRefGoogle Scholar
  19. 19.
    Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.CrossRefGoogle Scholar
  20. 20.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.CrossRefGoogle Scholar
  21. 21.
    Douglass H, Strablein D. Ten year follow-up of first generation surgical adjuvant studies of the Gastrointestinal Tumor Study Group. In: Salmon SE, editor. Adjuvant therapy of cancer, vol. 4. Philadelphia: WB Saunders; 1990. p. 404–15.Google Scholar
  22. 22.
    Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg. United States. 2006;244:332–33; author reply 333.CrossRefGoogle Scholar
  23. 23.
    Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21(2):195–200.CrossRefGoogle Scholar
  24. 24.
    Spalding DR. Pancreatic and periampullary cancers: treatment and outcome. Br J Hosp Med (Lond). 2006;67(1):14–20.CrossRefGoogle Scholar
  25. 25.
    Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.CrossRefGoogle Scholar
  26. 26.
    Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.CrossRefGoogle Scholar
  27. 27.
    Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90.CrossRefGoogle Scholar
  28. 28.
    Picozzi VJ, Abrams RA, Decker PA, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011;22(2):348–54.CrossRefGoogle Scholar
  29. 29.
    Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2000;48(5):1483–7.CrossRefGoogle Scholar
  30. 30.
    Reni M, Passoni P, Bonetto E, et al. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology. 2005;68(2–3):239–45.CrossRefGoogle Scholar
  31. 31.
    Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs. 2007;67(16):2293–310.CrossRefGoogle Scholar
  32. 32.
    Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704 – a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012;82(2):809–16.CrossRefGoogle Scholar
  33. 33.
    Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.CrossRefGoogle Scholar
  34. 34.
    Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918–22.CrossRefGoogle Scholar
  35. 35.
    Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel-l immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17(1):94–100; discussion p 100–1.CrossRefGoogle Scholar
  36. 36.
    NewLink Genetics announces results from phase 3 IMPRESS trial of algenpantucel-l for patients with resected pancreatic cancer [press release]. 2016.; http://investors.linkp.com/releasedetail.cfm?releaseid=969978. Accessed 4 May 2017.
  37. 37.
    Opfermann KJ, Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Am J Clin Oncol. 2014;37(2):112–6.CrossRefGoogle Scholar
  38. 38.
    Rutter CE, Park HS, Corso CD, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. Cancer. 2015;121(23):4141–9.CrossRefGoogle Scholar
  39. 39.
    McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19(22):4202–8.CrossRefGoogle Scholar
  40. 40.
    Blackstock AW, Mornex F, Partensky C, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95(3):260–5.CrossRefGoogle Scholar
  41. 41.
    Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):801–8.CrossRefGoogle Scholar
  42. 42.
    Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol. 2008;15(10):2773–86.CrossRefGoogle Scholar
  43. 43.
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–79.CrossRefGoogle Scholar
  44. 44.
    Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40(4):549–58.CrossRefGoogle Scholar
  45. 45.
    Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–210; discussion 1210–1191.CrossRefGoogle Scholar
  46. 46.
    Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27(3):324–9.CrossRefGoogle Scholar
  47. 47.
    Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.CrossRefGoogle Scholar
  48. 48.
    Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46; discussion 846–838.CrossRefGoogle Scholar
  49. 49.
    Pancreatic Adenocarcinoma. NCCN clinical practice guidelines in oncology 2017; Version 1.2017. Accessed 26 Apr 2017.Google Scholar
  50. 50.
    Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68.CrossRefGoogle Scholar
  51. 51.
    Yamaguchi K, Okusaka T, Shimizu K, et al. Clinical practice guidelines for pancreatic cancer 2016 from the Japan Pancreas Society: a synopsis. Pancreas. 2017;46(5):595–604.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Adeel Kaiser
    • 1
  • William F. Regine
    • 1
  • Naimish Pandya
    • 1
  • Michael C. Garofalo
    • 1
  1. 1.Department of Radiation OncologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations